Exercise and Testosterone Therapy in Elderly Men With Physical Frailty
NCT00345969
Completed
The primary aim of this study is to determine, in hypogonadal older men with physical frailty, whether exercise training combined with testosterone replacement therapy can improve skeletal muscle strength, and lean mass, to a greater degree than exercise training alone.
Gender:
MALE
Ages:
65 years and above
Trial Updated:
01/22/2018
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Physical Frailty, Hip Fracture, Elective Hip Replacement, Hypogonadism
Register for Updates
Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
NCT02159469
Completed
Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/11/2018
Locations: Not set, Birmingham, Alabama +27 locations
Conditions: Hypogonadism
Register for Updates
Pharmacokinetic Study of Testosterone Enanthate
NCT01887418
Completed
Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
12/13/2017
Locations: Mens Health Boston, Brookline, Massachusetts
Conditions: Hypogonadism
Register for Updates
Safety and Efficacy Trial of Testosterone Undecanoate
NCT01765179
Completed
The purpose of the study is to determine if oral testosterone undecanoate is effective and safe in the treatment of low testosterone in men.
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
11/14/2017
Locations: Alabama Clinical Therapeutics, LLC, Birmingham, Alabama +26 locations
Conditions: Male Hypogonadism
Register for Updates
TRADE-Testosterone Replacement and Dutasteride Effectiveness
NCT00194675
Completed
The purpose of this research study is to determine whether the combination of the male hormone testosterone \[T\] in gel form and the oral drug dutasteride \[D\], used to shrink large prostate glands can safely reduce the size of the prostate gland and symptoms of prostate enlargement (called benign prostatic hyperplasia \[BPH\]) compared to T treatment alone in men with low testosterone (called hypogonadism).
Gender:
MALE
Ages:
50 years and above
Trial Updated:
10/30/2017
Locations: VA Puget Sound Health Care System, Seattle, Washington
Conditions: Hypogonadism, Benign Prostatic Hyperplasia
Register for Updates
Testosterone Replacement Therapy in Chronic Spinal Cord Injury
NCT00266864
Completed
It has long been recognized that co-morbidity associated with multiple metabolic syndrome, such as adverse body composition, insulin resistance and autonomic nervous system impairment, may lead to significant increase in cardiovascular morbidity and mortality. It is unclear whether the co-morbidity evident in this population are due directly to their immobility or are the result of unfavorable changes in their underlying hormonal milieu. The purpose of this study is to determine the effect of te... Read More
Gender:
MALE
Ages:
Between 18 years and 49 years
Trial Updated:
09/29/2017
Locations: Kessler Institute for Rehabilitation, West Orange, New Jersey +1 locations
Conditions: Spinal Cord Injury, Hypogonadism
Register for Updates
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel
NCT01665599
Completed
This is a Phase 3 clinical trial in adult hypogonadal males with baseline serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the safety and efficacy of testosterone gel (2%) delivered using an applicator.
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
09/25/2017
Locations: Medical Affiliated Research Cente, Huntsville, Alabama +18 locations
Conditions: Adult Male Hypogonadism
Register for Updates
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males
NCT02149264
Completed
This is a phase 3, open-label, non-randomized, clinical trial to evaluate the efficacy and safety of FE 999303 (Testosterone gel) in adult hypogonadal males.
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
09/25/2017
Locations: Investigational site, Anniston, Alabama +21 locations
Conditions: Adult Male Hypogonadism
Register for Updates
A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel
NCT01703741
Completed
This is a multicenter extension trial in adult hypogonadal males. The purpose of this study is to evaluate the safety of testosterone gel delivered using an applicator over an extended period of time.
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
09/19/2017
Locations: Medical Affiliated Research Center, Huntsville, Alabama +17 locations
Conditions: Adult Male Hypogonadism
Register for Updates
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
NCT00467870
Completed
To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/07/2017
Locations: Indevus Pharmaceuticals, Inc., Lexington, Massachusetts
Conditions: Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Register for Updates
Time to Eugonadal Range, Time to Steady State and Drying Time
NCT01228071
Completed
This is a multicenter, open-label, single arm trial to evaluate the time to eugonadal testosterone range after initial testosterone gel 2% application, time to steady state after after initiation of testosterone gel 2%, and drying time after application of testosterone gel 2%.
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
09/07/2017
Locations: Quality of Life Medical & Research Center, Tucson, Arizona +7 locations
Conditions: Male Hypogonadism
Register for Updates
PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
NCT01327495
Completed
The investigators will conduct a three-month, randomized, placebo-controlled trial comparing the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the prostate in healthy men who are treated with acyline to block gonadal androgen production.
Gender:
MALE
Ages:
Between 25 years and 55 years
Trial Updated:
09/07/2017
Locations: University of Washington, Seattle, Washington
Conditions: Healthy
Register for Updates